Ambu® Laryngeal Mask as an Intubation Conduit

NCT ID: NCT00272194

Last Updated: 2016-03-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-12-31
• Study Completion Date: 2007-04-30

Brief Summary

The purpose of this study is to determine if the Ambu Laryngeal Mask can be used as an intubation conduit for endotracheal intubation.

Detailed Description

The laryngeal mask airway (LMA) is an established supra-glottic device that provides better ventilation than traditional mask ventilation and is less invasive than endotracheal intubation. Being less invasive, it is commonly used for short elective surgical procedures. Its ability to be both easily and rapidly inserted also makes it useful as a rescue device in difficult and failed intubations. Being a supra-glottic device, the LMA does not protect patients from regurgitation and aspiration. Additionally, patients requiring alternative positions, such as prone or lateral, or those having surgery in the neck/head area are contra-indicated for LMA use due to risk of possible movement of the LMA, and therefore possible loss of airway patency. Thus, the LMA can be utilized as an intermediary method of airway management to endotracheal intubation.

The manufacturer of the reusable LMA-ClassicTM states that "the success rate of intubation through the standard LMA-ClassicTM is highly variable (30-93%)," whereas the success rate of the disposable version, LMA-UniqueTM, has been found to be only 21%1. An LMA specifically designed for intubation now exists and improves the success rate of intubation. The reusable LMA-FastrachTM or Intubating-LMATM (ILMA) is a rigid and anatomically curved airway tube. It is wide enough to accommodate 8.0 mm cuffed endotracheal tubes. Attached to the ILMA is a rigid handle to aid in one-handed insertion, removal, and adjustment. Success rates for intubating through the ILMA are 96.5% when inserted blindly and 100% with fiberoptic guidance2. No disposable version of the ILMA presently exists.

The Ambu® Laryngeal Mask (ALMA) is a new disposable laryngeal mask with an anatomical curve similar to the ILMA. The reasons for the use of disposable products can be many and varied. The residual risk of the transmission of germs and protein particles represents one indication. If supra-glottic airway devices are used electively or in emergencies, e.g. for HIV-positive patients or those infected with Creutzfeldt-Jacob disease, reuse of the products is not desirable. Disposable products, on the other hand, offer the benefit that the transmission of germs is avoided, and at the same time offer considerable economic advantages due to the much lower price of the product. The disposable ALMA has been proven as an effective and safe supra-glottic airway device3. Upon fiberoptic visualization through its shaft, the glottis was visualized 91.5% of the time, indicating that this device may be used as an intubation conduit. The purpose of this study is to determine if the ALMA is also safe and effective as an intubating conduit. The hypothesis is that the ALMA will perform as well as, if not better than the LMA-UniqueTM.

Conditions

Intubation, Endotracheal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: SINGLE

Interventions

Ambu Laryngeal Mask

Intervention Type: DEVICE

Aintree Exchange Catheter

Intervention Type: DEVICE

Laryngeal Mask Airway

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• The patient is ASA 1-3 presenting for an elective surgical procedure
• The patient is 18-65 years of age
• The patient weighs > 50 kg with a BMI < 30 kg/m2
• The patient has a Mallampati grade I -III airway
• The patient is undergoing general anesthesia with controlled ventilation for minor routine surgical procedures
• The period of anesthesia time is >30 minutes

Exclusion Criteria

• The patient is an ASA classification 4
• The patient is < 18 or >65 years of age
• The patient weighs < 50 kg or has a BMI > 30 kg/m2
• The patient has a history of inadequate cervical mobility
• The patient has a history or signs of difficult airway management
• The patient has a Mallampati grade IV Class airway
• The patient has a mouth opening < 2.5 cm
• The patient has an oral cavity disease
• The patient has a cervical malformation
• The patient had upper respiratory tract symptoms in the previous 10 days
• The patient is to have surgery performed to the head/neck or thoracoabdominal cavities needing to be paralyzed, or in the lateral/prone position
• The patient is considered at risk of aspiration (non-fasted, gastroesophageal reflux/disease)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ambu A/S

INDUSTRY

Sponsor Role: collaborator

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role: lead

Responsible Party

Carin A. Hagberg

Professor and Chairman, Joseph C. Gable, M.D., Endowed Chair

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Carin A. Hagberg, M.D.

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Medical School at Houston

Locations

Memorial Hermann Hospital

Houston, Texas, United States

Countries

United States

Other Identifiers

HSC-MS-05-0347

Identifier Type: -

Identifier Source: org_study_id